Fate Therapeutics (F6T) Price & Analysis

Compare

1 Followers

F6T Stock Chart & Stats

€0.96

€0.07(3.83%)

At close: Jan 08 4:00 PM EST

€0.96

€0.07(3.83%)

Day’s Range― - ―

52-Week Range€0.60 - €1.62

Previous CloseN/A

Volume185.00

Average Volume (3M)355.00

Market Cap

€116.61M

Enterprise Value€163.61M

Total Cash (Recent Filing)€215.42M

Total Debt (Recent Filing)€79.25M

Price to Earnings (P/E)―

Beta0.55

Next Earnings

Mar 02, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.23

Shares Outstanding115,352,290

10 Day Avg. Volume358

30 Day Avg. Volume355

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)0.59

Price to Sales (P/S)13.76

P/FCF Ratio-1.52

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€3.23

Price Target Upside236.08% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Autoimmune Registrational PathwayPromising Phase I outcomes for FT819, including drug-free remission and complete renal responses, support a potential registrational trial in SLE and lupus nephritis.

CAR-T Administration InnovationFirst patient dosing with FT836, a MICA/B-targeting CAR-T engineered for administration without conditioning, could broaden eligibility and simplify outpatient treatment logistics.

Financial RunwayA cash position near $226 million provides multi-year funding capacity to advance clinical programs and planned trials.

Bears Say

Analyst SentimentAnalyst maintains a Hold rating citing mixed durability data, which may sustain caution among investors and limit upside momentum.

B-cell Aplasia DurabilityMixed durability of B-cell aplasia, particularly in patients who received no conditioning, raises concern over the consistency of long-term therapeutic benefit.

Regulatory And Commercial Risk For No-conditioning CAR-TDurability uncertainties for no-conditioning CAR-T candidates could complicate regulatory assessment and slow adoption by clinicians and payors.

Fate Therapeutics News

Fate Therapeutics presents updated Phase 1 data of FT819

Fate Therapeutics (FATE) presented updated clinical data from its ongoing Phase 1 trial evaluating its FT819 off-the-shelf iPSC-derived...

2M ago

FATE

Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts

Fate Therapeutics Inc ( ($FATE) ) has released its Q3 earnings. Here is a breakdown of the information...

3M ago

FATE

Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks

Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Environmental / Social category. Fate Therapeutics Inc....

3M ago

FATE

Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment

TD Cowen analyst Tara Bancroft has maintained their neutral stance on FATE stock, giving a Hold rating on...

3M ago

FATE

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

Reports Q3 revenue $1.741M, consensus $1.68M. “The potentially transformative impact of FT819 in lupus is at an inflection...

3M ago

FATE

Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Robert Burns upgraded Fate Therapeutics (FATE) to Buy from Neutral with a $5 price target...

4M ago

FATE

Is FATE a Buy, Before Earnings?

Fate Therapeutics Inc (FATE) is scheduled to report 3rd quarter earnings on 10/30/2025. Regarding Q3 estimates, Wall Street...

4M ago

FATE

Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is conducting a...

4M ago

FATE

Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Study Overview: Fate Therapeutics Inc. is...

4M ago

FATE

Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment

Fate Therapeutics Inc (($FATE)) announced an update on their ongoing clinical study. Fate Therapeutics Inc. is conducting a...

4M ago

FATE

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

As previously reported, Wedbush analyst Martin Fan upgraded Fate Therapeutics (FATE) to Outperform from Neutral with a price...

4M ago

FATE

Fate Therapeutics Reports Promising Phase 1 Trial Results

The latest update is out from Fate Therapeutics ( ($FATE) ). On October 26, 2025, Fate Therapeutics announced...

4M ago

FATE

Fate Therapeutics upgraded to Outperform from Neutral at Wedbush

Wedbush upgraded Fate Therapeutics (FATE) to Outperform from Neutral with a price target of $7, up from $5....

4M ago

FATE

Hold Rating Maintained for Fate Therapeutics’ FT819 Amid Efficacy and Durability Concerns

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating on October...

4M ago

FATE

F6T FAQ

What was Fate Therapeutics Inc’s price range in the past 12 months?

Fate Therapeutics Inc lowest stock price was €0.60 and its highest was €1.62 in the past 12 months.

What is Fate Therapeutics Inc’s market cap?

Fate Therapeutics Inc’s market cap is €116.61M.

When is Fate Therapeutics Inc’s upcoming earnings report date?

Fate Therapeutics Inc’s upcoming earnings report date is Mar 02, 2026 which is in 16 days.

How were Fate Therapeutics Inc’s earnings last quarter?

Fate Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -€0.227 earnings per share for the quarter, beating the consensus estimate of -€0.246 by €0.019.

Is Fate Therapeutics Inc overvalued?

According to Wall Street analysts Fate Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fate Therapeutics Inc pay dividends?

Fate Therapeutics Inc does not currently pay dividends.

What is Fate Therapeutics Inc’s EPS estimate?

Fate Therapeutics Inc’s EPS estimate is -0.23.

How many shares outstanding does Fate Therapeutics Inc have?

Fate Therapeutics Inc has 115,352,290 shares outstanding.

What happened to Fate Therapeutics Inc’s price movement after its last earnings report?

Fate Therapeutics Inc reported an EPS of -€0.227 in its last earnings report, beating expectations of -€0.246. Following the earnings report the stock price went down -6.838%.

Which hedge fund is a major shareholder of Fate Therapeutics Inc?

Currently, no hedge funds are holding shares in DE:F6T

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Fate Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-52.35%

Trailing 12-Months

Asset Growth

-30.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics (F6T) Earnings & Revenues

Historic Earnings Reports

F6T Stock 12 Month Forecast

Average Price Target

€3.23

▲(236.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","-1":"-€1","0.75":"€0.75","2.5":"€2.5","4.25":"€4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.89682744,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€5.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.2264070136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.68480784,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.68</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.937,1.3185251876923076,1.7000503753846155,2.081575563076923,2.4631007507692306,2.8446259384615384,3.2261511261538462,3.607676313846154,3.989201501538462,4.37072668923077,4.7522518769230775,5.133777064615385,5.515302252307692,{"y":5.89682744,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.937,1.1131082318153847,1.2892164636307692,1.4653246954461538,1.6414329272615387,1.817541159076923,1.9936493908923079,2.1697576227076922,2.345865854523077,2.521974086338462,2.6980823181538462,2.8741905499692306,3.0502987817846154,{"y":3.2264070136,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.937,0.99452368,1.05204736,1.10957104,1.1670947200000001,1.2246184,1.28214208,1.33966576,1.39718944,1.45471312,1.5122368,1.56976048,1.6272841599999999,{"y":1.68480784,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.339,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.037,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.715,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.005,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.023,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.917,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.927,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.895,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.032,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.158,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.933,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.817,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.937,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >